Biomolecular Life Holdings, Inc. Reaches Another Milestone as It Prepares to Acquire Dr Dacon Medicina Biológica SAS, the Medical Practice of Dr. David Contreras

PR Newswire

MIAMI and BOGOTA, Colombia, Nov. 17, 2026

The planned acquisition would bring an established biomolecular therapy practice, led by a  renowned physician and expert in biomolecular therapy, and its clinic property in Bogotá's prestigious Santa Bárbara district into BIOM's integrated health and wellness platform.

MIAMI and BOGOTA, Colombia, Nov. 17, 2026 /PRNewswire/ -- Biomolecular Life Holdings, Inc. (OTC: BIOM), a health and wellness holding company focused on biomolecular nutrition, wellness technologies and longevity-oriented solutions, today announced that it is preparing to acquire Dr Dacon Medicina Biológica SAS ("Dr Dacon"), the Colombian medical practice of Dr. David Contreras, a renowned Colombian physician and expert in biological medicine and biomolecular therapy. The acquisition includes the real estate of the practice's clinic, located in Santa Bárbara, one of Bogotá's most prestigious neighborhoods, directly across from the Fundación Santa Fe de Bogotá University Hospital.

BIOM logo

The planned acquisition marks another milestone in BIOM's strategy to build an integrated biomolecular health platform. It follows the Company's letter of intent to acquire Biomolecular Life LLC, Dr. Contreras's nutritional supplement company for people and pets, and its agreement to acquire land in Llanogrande, Antioquia, for a planned Biomolecular Wellness Spa and Longevity Retreat.

Upon completion, Dr Dacon would become the Company's clinical arm, providing medical expertise and professional oversight for its biomolecular therapy programs, including those planned for the Llanogrande retreat.

The Company has signed a non-binding letter of intent to acquire Dr Dacon. The transaction includes both the medical practice and its clinic property. The terms, including the consideration and the valuation of the property by independent appraisal, have not yet been finalized and will be disclosed upon execution of a definitive agreement. Completion is subject to due diligence, a definitive agreement, applicable regulatory requirements and customary closing conditions. Because of Dr. Contreras's relationship with BIOM, the proposed transaction would constitute a related-party transaction.

Investment Highlights

Management believes the planned acquisition offers shareholders the following potential advantages:

About Dr. David Contreras

Dr. David Contreras is a renowned Colombian physician with extensive experience in biological medicine, biomolecular therapy and regenerative medicine. His career combines clinical practice, academic training, research and social programs in Colombia and internationally, and he currently leads the development and expansion of the Biomolecular Life brand.

Dr. Contreras began his medical career with the Colombian Battalion No. 3 in the Sinai Peninsula, where he worked in the clinic of the multinational peacekeeping force and took part in medical evacuations. He studied medicine at Nueva Granada Military University, trained in pain management and rehabilitation at the Naval Hospital, treating members of Colombia's Armed Forces injured in the conflict, including landmine survivors, and completed postgraduate studies in homotoxicology at El Bosque University.

Since 2000 he has worked with international professionals and organizations in biological therapy, including scientific activities with the Sicacell and Sibila laboratories in Europe. In 2010 he trained in biomolecular therapy in Stuttgart, Germany. His research in molecular biology, cell reprogramming and induced pluripotent stem cells (iPSCs) includes work at The Hormel Institute, University of Minnesota, and he contributed to the publication "Cellular Molecular Therapy" in Hong Kong.

Dr. Contreras has treated and trained patients and professionals from Colombia, Venezuela, Guatemala, Mexico, Costa Rica, Peru, Argentina, Ecuador, Israel, Japan, the United States and Russia. Through Dr Dacon Medicina Biológica SAS, whose clinic is located in Santa Bárbara, Bogotá, across from the Fundación Santa Fe de Bogotá University Hospital, he and his team provide biological and biomolecular medicine services. Through the Da Vida Foundation, he also helps low-income communities access health support programs.

Building an Integrated Biomolecular Health Platform

The planned acquisition of Dr Dacon is the latest in a series of steps toward a single platform spanning products, clinical care and wellness hospitality:

Leadership Comments

"Bringing Dr. Contreras's medical practice into Biomolecular Life Holdings is another important milestone for our Company," said Jessika Wiesner, President and Chief Executive Officer of Biomolecular Life Holdings, Inc.

"Dr. Contreras is a renowned physician and a leading expert in biomolecular therapy. His practice gives us the clinical foundation to connect our products, our planned wellness destination in Llanogrande and the medical expertise that patients and guests expect."

"For years, my team and I have focused on helping patients through biomolecular therapy and preventive medicine," said Dr. David Contreras. "Joining Biomolecular Life Holdings will allow us to reach more patients, expand our programs internationally and bring our approach to a platform built for growth."

About Biomolecular Life Holdings, Inc.

Biomolecular Life Holdings, Inc. (OTC: BIOM) is a health and wellness holding company focused on biomolecular nutritional products, personalized wellness programs, advanced wellness technologies and longevity-oriented solutions.

The Company manages the marketing of the Biomolecular Life nutraceutical product line and has signed a letter of intent to acquire Biomolecular Life LLC. It has also agreed to acquire land in Llanogrande, Colombia, for a planned Biomolecular Wellness Spa and Longevity Retreat, and is preparing to acquire Dr Dacon Medicina Biológica SAS, the medical practice of Dr. David Contreras, together with its clinic property in Bogotá.

For additional information, visit www.biomolecularlifeinc.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the proposed acquisition of Dr Dacon Medicina Biológica SAS, its timing, terms and expected benefits, the valuation and transfer of the clinic property, the integration of the practice, future revenue, and the Company's other planned acquisitions and projects.

These statements reflect management's current expectations and are subject to risks and uncertainties, including the negotiation and execution of a definitive agreement, the results of due diligence, the satisfaction of closing conditions, regulatory and licensing requirements applicable to medical practices in Colombia, the ability to integrate the practice and retain key personnel, the availability of financing, market conditions and other factors that could cause actual results to differ materially from those expressed or implied.

The Company undertakes no obligation to update or revise forward-looking statements except as required by applicable law.

Media and Investor Relations Contact
Biomolecular Life Holdings, Inc.
1395 Brickell Ave., Suite 800
Miami, FL 33131
Email: info@biomolecularlifeholdingsinc.com
Phone: 877-646-4833
Website: www.biomolecularlifeinc.com
OTC: BIOM

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomolecular-life-holdings-inc-reaches-another-milestone-as-it-prepares-to-acquire-dr-dacon-medicina-biologica-sas-the-medical-practice-of-dr-david-contreras-302941635.html

SOURCE Biomolecular Life Holdings Inc